Lung cancer
Lung cancer occurs in the bronchial mucosa or glands, also known as bronchial lung cancer. In the past 50 years, many countries have reported that the incidence of lung cancer has increased significantly. Among male cancer patients, lung cancer has ranked first, and the incidence rate in women has also increased rapidly, accounting for the second or third most common malignant tumors in women. The male-female incidence ratio is 3~5:1, and the age of onset is mostly between 60-79 years old. The cause of lung cancer is still not completely clear. A large amount of data shows that long-term heavy smoking is an important pathogenic factor of lung cancer. For those who smoke more than 40 cigarettes a day for many years, the incidence of squamous cell carcinoma and undifferentiated cancer of the lung is 4 to 10 times higher than that of non-smokers. The incidence of lung cancer in urban residents is higher than that in rural areas, which may be related to air pollution and carcinogens contained in smoke. Therefore, non-smoking should be advocated and urban environmental sanitation work should be strengthened.
-
Site of disease:
lung -
Infectious :
Not contagious -
Frequent population:
Male smoker aged 40 years and above -
Related symptoms:
Lung mass Sputum has a foul smell Shoulder and back pain Cough Coughing up phlegm -
Concurrent disease:
Related Drugs
Vinorelbine Bitartrate for Injection
Indication: Anti-tumor drug used for non-small cell lung cancer, breast cancer, refractory lymphoma, ovarian cancer, etc.
Manufacturer:
Hainan Tongyong Kangli Pharmaceutical Co., Ltd.
Vinorelbine Bitartrate for Injection
Indication: Anti-tumor drug used for non-small cell lung cancer, breast cancer, refractory lymphoma, ovarian cancer, etc.
Vinorelbine Bitartrate for Injection
Indication: Anti-tumor drug used for non-small cell lung cancer, breast cancer, refractory lymphoma, ovarian cancer, etc.
Vinorelbine tartrate injection
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphadenopathy, etc.
Manufacturer:
Han Hui Pharmaceuticals Company Limited
Erlotinib Hydrochloride Tablets
Indication: 1. Erlotinib alone is indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one chemotherapy regimen. 2. In two multicenter, randomized, placebo-controlled Phase III trials, the results showed that erlotinib combined with platinum-containing chemotherapy (carboplatin-paclitaxel; or gemcitabine-cisplatin) as first-line treatment for patients with locally advanced or metastatic NSCLC did not increase clinical benefit compared with platinum-containing chemotherapy alone, so it is not recommended for first-line treatment in the above situation. 3. Erlotinib alone can be used for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease is stable after 4 cycles of platinum-based first-line chemotherapy. This indication is based on the results of a randomized, double-blind, placebo-controlled study (B018192) [see [Clinical Trials]]. No clinical research data comparing the use of erlotinib for treatment without progression and after progression after first-line chemotherapy have been obtained. 4. Clinical research on this product for first-line treatment of EGFR mutation populations is ongoing. It is recommended that the treating physician consider appropriate treatment options based on the research progress of this product and similar drugs and the patient's own condition.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Hainan Quanxing Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Guangdong Sunho Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Related Ingredients